Dr. Frances Kelsey and the Thalidomide Decision in the US
This paper evaluates Dr. Frances Kelsey's decision to block the approval of thalidomide in the United States in 1960, set against the backdrop of a widespread birth defect crisis in Europe. Drawing on historical accounts and medical research, the paper traces how independent physicians in Australia and Germany identified thalidomide as the cause of severe fetal malformations, how the drug's manufacturer continued to press for U.S. approval despite mounting evidence, and how Kelsey's insistence on rigorous proof ultimately protected American mothers and their unborn children. The paper also notes the drug's later FDA-approved use as a treatment for a complication of leprosy, and concludes that Kelsey's cautious stance was justified.
- Introduction and Background: Frames the central question about Kelsey's decision
- The European Thalidomide Disaster: Documents birth defects and scale of European crisis
- Dr. Kelsey's Decision and FDA Resistance: Details Merrell's lobbying and Kelsey's rejection
- Later Research and Approved Uses of Thalidomide: FDA approves thalidomide for leprosy complication
- Conclusion: Argues Kelsey's caution was ultimately justified
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- It frames a historical regulatory decision as an ethical question and answers it with evidence, giving the analysis a clear argumentative purpose.
- It balances the case for Kelsey's caution against the counterargument that the FDA later introduced unnecessary delays, acknowledging complexity without losing focus.
- It closes by connecting the historical case to a broader principle — that erring on the side of caution in drug approval can be the right call — making the conclusion feel earned rather than merely asserted.
Key academic technique demonstrated
The paper uses a single well-documented historical case study as the evidentiary basis for a normative conclusion. By reconstructing the sequence of events — the European crisis, Merrell's continued lobbying, Kelsey's rejection, and the drug's eventual limited approval — the author demonstrates how a chronological evidence chain can support a policy judgment without overgeneralizing.
Structure breakdown
The paper opens with a brief framing of the central question, then builds context through the European disaster, the FDA approval fight, and thalidomide's later medical rehabilitation. A short conclusion weighs the broader implications for drug regulation. The structure is straightforward and appropriate for the paper's length and undergraduate scope.
Introduction and Background
Although the United States succeeded in averting the thalidomide tragedy that occurred in Europe by refusing to approve the drug, some observers counter that this action introduced unnecessary delays in the approval of many useful drugs. Given that thalidomide is now accepted as an effective treatment for leprosy, this paper evaluates whether Dr. Frances Kelsey was correct in stopping the development of thalidomide in the United States in 1960, followed by a summary of the research and important findings in the conclusion.
The European Thalidomide Disaster
In 1961, two doctors working independently in Australia and Germany determined that thalidomide — a sedative and anti-nausea drug being prescribed for pregnant women — was responsible for a wave of birth defects (Carpenter, 2010). Based on their analysis of available data, the two physicians, Drs. McBride and Lenz, determined that thalidomide caused birth defects when taken during the first trimester of pregnancy (Carpenter, 2010). As Carpenter reports, "Tragically, thousands of pregnant women had taken thalidomide during this window of pregnancy because of its utility as an anti-nausea drug" (2010, p. 240).
Beyond the dozens of high-profile physical deformities caused by thalidomide, additional thousands suffered from brain and internal organ damage (Carpenter, 2010). The actual number of women who experienced stillbirths as a result of taking thalidomide has never been determined (Carpenter, 2010). Brown (2009) estimates that approximately 10,000 infants had been born with severe limb malformations by 1961 to women who took thalidomide during their pregnancies, and countless more pregnancies were aborted.
Dr. Kelsey's Decision and FDA Resistance
Following the two physicians' warnings, the drug was recalled from European markets by the European manufacturer. However, the U.S. pharmaceutical company Merrell continued to press its case for approval of thalidomide to Dr. Frances Kelsey, a medical officer with the Food and Drug Administration (FDA), arguing that the mounting evidence from Europe was erroneous with respect to the reported birth abnormalities and that the drug should still be approved in the United States (Carpenter, 2010).
According to Carpenter, "Kelsey rejected this assertion and again imposed the burden of proof upon Merrell. As the stories became more numerous and as the link between drug and defects became clearer, Merrell quietly withdrew the new drug application in March 1962" (2010, p. 240). Consequently, while more than a million doses of thalidomide were being taken by pregnant women in West Germany in 1960, expecting mothers and their unborn children in the United States were protected from the ravages of this drug by the actions of Dr. Kelsey.
Conclusion
Tens of millions of American baby boomer parents owe a debt of gratitude to Dr. Frances Kelsey for her actions in preventing thalidomide from being approved for its intended use in the United States. The regulatory caution that the FDA would be charged with in the years following Dr. Kelsey's decision cannot be reasonably attributed to this one case alone, and alternative — and safer — uses of drugs are discovered regularly, though even these must pass FDA scrutiny for new applications. Although it is reasonable to conclude that the FDA has at times introduced delays in the approval process since the early 1960s, the thalidomide case is proof that in some circumstances it is better to err on the side of caution.
References
Annas, G., & Elias, S. (1999, January). Thalidomide and the Titanic: Reconstructing the technology tragedies of the twentieth century. American Journal of Public Health, 89(1), 98–101.
Brown, V. J. (2009, February). New insights into thalidomide. Environmental Health Perspectives, 117(2), 61.
Carpenter, D. (2010). Reputation and power: Organizational image and pharmaceutical regulation at the FDA. Princeton University Press.
Create your account
Always verify citation format against your institution’s current style guide requirements.